Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event | Zendy

Michał Karliński | Zendy; Adam Kobayashi | Zendy; Anna Członkowska | Zendy; Robert Mikulík | Zendy; Daniel Václavík | Zendy; M Brozman | Zendy; Zuzana Gdovinová | Zendy; Viktor Švigelj | Zendy; László Csiba | Zendy; Klára Fekete | Zendy; Janika Kõrv | Zendy; Vida Demarin | Zendy; Vanja Bašić-Kes | Zendy; Aleksandras Vilionskis | Zendy; Dalius Jatužis | Zendy; Yakup Krespi | Zendy; N. А. Shamalov | Zendy; Silva Andonova | Zendy; Niaz Ahmed | Zendy; Nils Wahlgren | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous Thrombolysis for Stroke Recurring Within 3 Months From the Previous Event

Author(s) -

Michał Karliński,

Adam Kobayashi,

Anna Członkowska,

Robert Mikulík,

Daniel Václavík,

M Brozman,

Zuzana Gdovinová,

Viktor Švigelj,

László Csiba,

Klára Fekete,

Janika Kõrv,

Vida Demarin,

Vanja Bašić-Kes,

Aleksandras Vilionskis,

Dalius Jatužis,

Yakup Krespi,

N. А. Shamalov,

Silva Andonova,

Niaz Ahmed,

Nils Wahlgren

Publication year - 2015

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.115.010420

Subject(s) - medicine , thrombolysis , stroke (engine) , odds ratio , confidence interval , intracerebral hemorrhage , odds , logistic regression , physical therapy , pediatrics , surgery , subarachnoid hemorrhage , myocardial infarction , mechanical engineering , engineering

According to the European license, alteplase can be given no sooner than 3 months after previous stroke. However, it is not known whether past history of stroke influences the effect of treatment. Our aim was to evaluate safety and functional outcome after intravenous thrombolysis administered in everyday practice to patients with previous stroke≤3 months compared with those with first-ever stroke.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research